C M Clark

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease
    C M Clark
    Department of Neurology, Alzheimer s Disease Center, University of Pennsylvania, Philadelphia 19104, USA
    Arch Neurol 56:857-62. 1999
  2. ncbi Earlier onset of Alzheimer disease symptoms in latino individuals compared with anglo individuals
    Christopher M Clark
    Department of Neurology, Alzheimer s Disease Center, University of Pennsylvania, Philadelphia 19104, USA
    Arch Neurol 62:774-8. 2005
  3. ncbi Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
    Christopher M Clark
    Departments of Neurology, Center for Neuerodegenerative Disease Research, Alzheimer s Disease Center, Philadelphia, PA 19104, USA
    Arch Neurol 60:1696-702. 2003
  4. pmc CSF biomarkers in frontotemporal lobar degeneration with known pathology
    H Bian
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Neurology 70:1827-35. 2008
  5. ncbi Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease
    Murray Grossman
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Ann Neurol 57:721-9. 2005
  6. ncbi Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
    Manuela Neumann
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Science 314:130-3. 2006
  7. pmc Novel CSF biomarkers for frontotemporal lobar degenerations
    W T Hu
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia 19104 4283, USA
    Neurology 75:2079-86. 2010
  8. pmc Frontotemporal dementia: clinicopathological correlations
    Mark S Forman
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Ann Neurol 59:952-62. 2006
  9. ncbi Quantitative neurohistological features of frontotemporal degeneration
    S E Arnold
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Neurobiol Aging 21:913-9. 2000
  10. pmc Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI
    C Davatzikos
    Section of Biomedical Image Analysis, Department of Radiology, University of Pennsylvania, 3600 Market Street, Suite 380, Philadelphia, PA 19104, USA
    Neuroimage 41:1220-7. 2008

Detail Information

Publications67

  1. ncbi Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease
    C M Clark
    Department of Neurology, Alzheimer s Disease Center, University of Pennsylvania, Philadelphia 19104, USA
    Arch Neurol 56:857-62. 1999
    ..To determine the variability in annual Mini-Mental State Examination scores of patients with Alzheimer disease enrolled in the Consortium to Establish a Registry for Alzheimer's Disease (CERAD)...
  2. ncbi Earlier onset of Alzheimer disease symptoms in latino individuals compared with anglo individuals
    Christopher M Clark
    Department of Neurology, Alzheimer s Disease Center, University of Pennsylvania, Philadelphia 19104, USA
    Arch Neurol 62:774-8. 2005
    ....
  3. ncbi Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
    Christopher M Clark
    Departments of Neurology, Center for Neuerodegenerative Disease Research, Alzheimer s Disease Center, Philadelphia, PA 19104, USA
    Arch Neurol 60:1696-702. 2003
    ..To understand their value as predictors of disease-specific pathology, levels determined during life must be correlated with definitive diagnoses in mixed dementia groups and cognitively normal subjects...
  4. pmc CSF biomarkers in frontotemporal lobar degeneration with known pathology
    H Bian
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Neurology 70:1827-35. 2008
    ..To evaluate the diagnostic value of CSF biomarkers in patients with known pathology due to frontotemporal lobar degeneration (FTLD)...
  5. ncbi Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease
    Murray Grossman
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Ann Neurol 57:721-9. 2005
    ..We conclude that CSF tau levels are significantly reduced in many patients with FTD...
  6. ncbi Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
    Manuela Neumann
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Science 314:130-3. 2006
    ..TDP-43 represents the common pathologic substrate linking these neurodegenerative disorders...
  7. pmc Novel CSF biomarkers for frontotemporal lobar degenerations
    W T Hu
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia 19104 4283, USA
    Neurology 75:2079-86. 2010
    ..To identify antemortem CSF diagnostic biomarkers that can potentially distinguish between the 2 main causes of frontotemporal lobar degeneration (FTLD), i.e., FTLD with TDP-43 pathology (FTLD-TDP) and FTLD with tau pathology (FTLD-tau)...
  8. pmc Frontotemporal dementia: clinicopathological correlations
    Mark S Forman
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Ann Neurol 59:952-62. 2006
    ..This study assessed whether specific clinical features predict the underlying pathology...
  9. ncbi Quantitative neurohistological features of frontotemporal degeneration
    S E Arnold
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Neurobiol Aging 21:913-9. 2000
    ..The molecular neurodegenerative mechanisms that lead to FTD remain to be elucidated...
  10. pmc Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI
    C Davatzikos
    Section of Biomedical Image Analysis, Department of Radiology, University of Pennsylvania, 3600 Market Street, Suite 380, Philadelphia, PA 19104, USA
    Neuroimage 41:1220-7. 2008
    ..In conclusion, AD- and FTD-specific patterns of brain atrophy can be detected with high accuracy using high-dimensional pattern classification of MRI scans obtained in a typical clinical setting...
  11. pmc Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment
    William T Hu
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Acta Neuropathol 119:669-78. 2010
    ..In summary, our targeted proteomic screen revealed novel CSF biomarkers that can improve the distinction between AD and non-AD cases by established biomarkers alone...
  12. ncbi Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease
    H I Hurtig
    Department of Neurology, University of Pennsylvania, PA, USA
    Neurology 54:1916-21. 2000
    ..Although Alzheimer's pathology has been a frequent finding, recent advances in immunostaining of alpha-synuclein have suggested the possible importance of cortical Lewy bodies (CLBs) in the brains of demented patients with PD...
  13. ncbi Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia
    V Zhukareva
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA
    Ann Neurol 49:165-75. 2001
    ..The presence of tau mRNA in these brains suggests that the level of tau protein may be controlled posttranscriptionally, at the level of either translation or mRNA stability...
  14. pmc Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations
    A S Chen-Plotkin
    Center for Neurodegenerative Disease Research, Institute on Aging and Department of Pathology and Laboratory Medicine, University of Pennsylvania Health System, Philadelphia, PA 19104, USA
    Neurology 70:521-7. 2008
    ..Despite pleomorphic pathology, LRRK2 mutations are believed to manifest clinically as typical Parkinson disease (PD). However, most genetic screens have been limited to PD clinic populations...
  15. ncbi Cognitive and motor assessment in autopsy-proven corticobasal degeneration
    R Murray
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Neurology 68:1274-83. 2007
    ..To investigate the clinical features of autopsy-proven corticobasal degeneration (CBD)...
  16. doi F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients
    James Connolly
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, Pennsylvania Hospital, Philadelphia, PA 19107, USA
    Cogn Behav Neurol 21:83-6. 2008
    ..To determine the utility of 8,12-isoprostaneF2alpha-VI (iP), a specific and sensitive index of lipid peroxidation, as a biomarker for dementia in Parkinson disease (PD)...
  17. ncbi Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations
    Vivianna M Van Deerlin
    Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Arch Neurol 64:1148-53. 2007
    ..Patients with frontotemporal dementia due to mutation of progranulin may have a distinct phenotype...
  18. ncbi Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases
    Hanae Nakashima-Yasuda
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, HUP Maloney 3rd Floor, Philadelphia, PA 19104 4283, USA
    Acta Neuropathol 114:221-9. 2007
    ..This study expands the concept of TDP-43 proteinopathies by implicating TDP-43 lesions in mechanisms of neurodegeneration in LB disorders...
  19. ncbi Relationship between Alzheimer's disease severity and patient participation in decisions about their medical care
    Jason H T Karlawish
    Department of Medicine, University of Pennsylvania, Philadelphia, USA
    J Geriatr Psychiatry Neurol 15:68-72. 2002
    ..Beyond mild-stage disease, the clinician can largely expect that the caregiver is making the final decisions. These results illustrate how and when caregivers can expect changes in their decision making role...
  20. pmc Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology
    Roy Hamilton
    Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
    Ann Neurol 68:535-40. 2010
    ....
  21. pmc Biomarkers for early detection of Alzheimer pathology
    C M Clark
    Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neurosignals 16:11-8. 2008
    ..Success will facilitate the ability to reliably diagnose Alzheimer's disease while the symptoms of brain failure are mild and may provide objective measures of disease-modifying treatment efficacy...
  22. ncbi The relationship between caregivers' global ratings of Alzheimer's disease patients' quality of life, disease severity, and the caregiving experience
    J H Karlawish
    Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Am Geriatr Soc 49:1066-70. 2001
    ..These results provide a compelling reason why clinicians should take the time to screen for and address caregiver depression and burden and problematic patient behaviors...
  23. pmc Rate of decline in Alzheimer disease measured by a Dementia Severity Rating Scale
    Sharon X Xie
    Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104 6021, USA
    Alzheimer Dis Assoc Disord 23:268-74. 2009
    ..To measure clinically relevant change in Alzheimer disease (AD) using a family member-completed Dementia Severity Rating Scale (DSRS) questionnaire...
  24. pmc Simultaneous HPLC-MS-MS quantification of 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha) in CSF and brain tissue samples with on-line cleanup
    Magdalena Korecka
    Department Pathology and Laboratory Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 878:2209-16. 2010
    ..1g of tissue for 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha)-VI, respectively, for the brain tissue method. No ion suppression or enhancement of the detection of 8-isoPGF(2alpha), 8,12-isoPF(2alpha)-VI or both internal standards was found...
  25. ncbi Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Nat Rev Drug Discov 6:295-303. 2007
    ....
  26. pmc Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects
    John Q Trojanowski
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Alzheimers Dement 6:230-8. 2010
    ..Further studies in ADNI will refine this model and render the biomarkers studied in ADNI more applicable to routine diagnosis and to clinical trials of disease modifying therapies...
  27. pmc Early marker for Alzheimer's disease: hippocampus T1rho (T(1rho)) estimation
    Mohammad Haris
    MMRRCC, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6100, USA
    J Magn Reson Imaging 29:1008-12. 2009
    ....
  28. pmc Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Ann Neurol 65:403-13. 2009
    ..Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects...
  29. pmc Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis
    Lionel M Igaz
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 3600 Spruce St, 3rd Floor, Maloney Bldg, Philadelphia, PA 19104, USA
    Am J Pathol 173:182-94. 2008
    ..Therefore, regionally different pathogenic processes may underlie the development of abnormal TDP-43 proteinopathies...
  30. doi T1rho (T1ρ) MR imaging in Alzheimer's disease and Parkinson's disease with and without dementia
    Mohammad Haris
    Department of Radiology, Center for Magnetic Resonance and Optical Imaging, University of Pennsylvania, B1 Stellar Chance Laboratories, 422 Curie Boulevard, Philadelphia, PA 19104 6100, USA
    J Neurol 258:380-5. 2011
    ..The serial measurement of T(1ρ) in both AD and PD may provide the nature of disease progression and may contribute to their early diagnosis...
  31. ncbi TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions
    Murray Grossman
    Department of Neurology, University of Pennsylvania School of Medicine, 2 Gibson, 3400 Spruce St, Philadelphia, PA 19104 4283, USA
    Arch Neurol 64:1449-54. 2007
    ..TDP-43 is a major ubiquitinated disease protein in the pathologic condition of frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U)...
  32. ncbi Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia
    Murray Grossman
    Department of Neurology, 2 Gibson, University of Pennsylvania School of Medicine, 3400 Spruce St, Philadelphia, PA 19104 4283, USA
    Arch Neurol 64:1601-9. 2007
    ..Clinical-pathologic studies are crucial to understanding brain-behavior relations and improving diagnostic accuracy in neurodegenerative diseases...
  33. pmc T1rho MRI of Alzheimer's disease
    Arijitt Borthakur
    MMRRCC, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104 6100, USA
    Neuroimage 41:1199-205. 2008
    ....
  34. ncbi Why would caregivers not want to treat their relative's Alzheimer's disease?
    Jason H T Karlawish
    Department of Medicine, University of Pennsylvania, Philadelphia, USA
    J Am Geriatr Soc 51:1391-7. 2003
    ..To determine family caregivers' willingness to use Alzheimer's disease (AD)-slowing medicines and to examine the relationships between this willingness, dementia severity, and caregiver characteristics...
  35. ncbi Diagnostic evaluation of elderly patients with mild memory problems
    Jason H T Karlawish
    University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Ann Intern Med 138:411-9. 2003
    ..In addition, symptoms of memory problems may be reported by an observer rather than by the patient. These challenges warrant stepwise evaluation of elderly patients who present with symptoms of memory loss...
  36. ncbi Visual processing impairments and decrements in regional brain activity in Alzheimer's disease
    Salina J van Rhijn
    Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Clin Exp Neuropsychol 26:11-23. 2004
    ....
  37. ncbi Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment
    Yuemang Yao
    Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
    Ann Neurol 58:623-6. 2005
    ..These results suggest that the activation of this enzyme occurs early in the course of AD, before the onset of overt dementia, thereby implicating 12/15LOX-mediated lipid peroxidation in the pathogenesis of AD...
  38. ncbi Addressing the challenges of transforming laboratory advances into Alzheimer's Disease treatments
    Jason H T Karlawish
    Department of Medicine, Division of Geriatrics, Alzheimer s Disease Center, Center for Bioethics and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia 19104, USA
    Neurobiol Aging 23:1043-9. 2002
    ..In this model, the patient and caregiver are seen as interrelated subjects of both treatment and research and outcome measures reflect biomarkers of the disease, the functional morbidity of AD and the distress of caregiving...
  39. ncbi Visual perceptual functions predict instrumental activities of daily living in patients with dementia
    Guila Glosser
    Department of Neurology, University of Pennsylvannia School of Medicine, Philadelphia 19104 4283, USA
    Neuropsychiatry Neuropsychol Behav Neurol 15:198-206. 2002
    ..To assess relations between discrete visual perceptual functions commonly affected in patients with neurodegenerative dementia and the performance of instrumental activities of daily living (IADL)...
  40. ncbi Emotion-discrimination deficits in mild Alzheimer disease
    Christian G Kohler
    Department of Psychiatry, Univ of Pennsylvania, Philadelphia, PA, USA
    Am J Geriatr Psychiatry 13:926-33. 2005
    ..Mild Alzheimer disease (AD) preferentially affects temporal lobe regions, which represent important structures in memory and emotional processes. This study investigated emotion discrimination in people with mild AD, versus Caretakers...
  41. ncbi Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease
    Domenico Pratico
    Center for Experimental Therapeutics, University of Pennsylvania, BRB II III, Room 812, 421 Curie Blvd, Philadelphia, PA 19104
    Arch Neurol 59:972-6. 2002
    ..The pathological changes associated with AD have a long silent phase before the appearance of clinical symptoms. Several studies have shown that AD is preceded by a prodromal phase characterized by mild cognitive impairment (MCI)...
  42. ncbi Memory encoding and retrieval in frontotemporal dementia and Alzheimer's disease
    Guila Glosser
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia 19104 4283, USA
    Neuropsychology 16:190-6. 2002
    ..FTD patients' retained capacity for encoding new information into long-term declarative memory is likely due to relatively spared medial temporal lobe involvement...
  43. ncbi Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease
    Andrew B Newberg
    Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Nucl Med 47:748-54. 2006
    ..The pharmacologic safety profile of the compound was simultaneously assessed...
  44. ncbi Disturbed visual processing contributes to impaired reading in Alzheimer's disease
    Guila Glosser
    Department of Neurology Gates 3 West, University of Pennsylvania Medical Center, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
    Neuropsychologia 40:902-9. 2002
    ....
  45. pmc Sodium MR imaging detection of mild Alzheimer disease: preliminary study
    E A Mellon
    Department of Radiology, MMRRCC, University of Pennsylvania, Philadelphia, PA, USA
    AJNR Am J Neuroradiol 30:978-84. 2009
    ..Because MR imaging has detected alterations in sodium levels that correlate with cell death in stroke, we hypothesized that there would be alterations of sodium levels in the brains of patients with AD, related to AD cell death...
  46. pmc Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease
    William T Hu
    Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
    Acta Neuropathol 120:385-99. 2010
    ....
  47. ncbi Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study
    Victoria Zhukareva
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Maloney 3, HUP, 3600 Spruce Street, Philadelphia, PA 19104 4283, USA
    Acta Neuropathol 105:469-76. 2003
    ....
  48. pmc Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies
    Kunihiro Uryu
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Neuropathol Exp Neurol 67:555-64. 2008
    ..These findings provide further insight into the burden and clinical significance of TDP-43 pathology in disorders other than FTLD-U and amyotrophic lateral sclerosis...
  49. ncbi Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia
    Y Yao
    Center for Experimental Therapeutics, Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia 19104, USA
    Neurology 61:475-8. 2003
    ..To quantify the isoprostane 8,12-iso-iPF2alpha-VI in brain tissues obtained from patients with AD, patients with frontotemporal dementia (FTD), and controls...
  50. ncbi Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies
    Christopher M Clark
    Memory Disorders Clinic, Penn Ralston Center, University of Pennsylvania, 3615 Chestnut Street, Philadelphia, Pennsylvania 19104, USA
    Ann Intern Med 138:400-10. 2003
    ..If these new therapies are successful, they will represent a remarkable medical advance for patients and the families who care for them...
  51. ncbi Cognitive function assessment in individuals at risk for Alzheimer's disease
    Valerie T Cotter
    Adult Health and Gerontology Nurse Practitioner Programs, School of Nursing, Alzheimer s Disease Center, University of Pennsylvania, USA
    J Am Acad Nurse Pract 15:79-86. 2003
    ..To describe brief assessments of functional performance and cognition to detect Alzheimer's disease (AD) and depression in older adults for the primary care provider...
  52. pmc Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease
    J Nicholas Lukens
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA
    Alzheimers Dement 5:463-9. 2009
    ..We examined the correlation between PBL and cerebellum telomere length in AD patients, and compared telomere lengths in cerebella from individuals with AD versus age-matched control subjects...
  53. ncbi A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial
    J Quinn
    Department of Neurology, Portland Veteran s Affairs Medical Center, P3 R and D, 3710 SW US Veterans Hospital Road, Portland, OR 97201, USA
    Neurology 58:433-7. 2002
    ..The global impression of a clinician is an Food and Drug Administration--mandated primary outcome measure for clinical trials in dementia. Reliability and validity of these measures are not well established...
  54. ncbi Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia
    Charles DeCarli
    Department of Neurology and Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis, Sacramento 95817, USA
    Arch Neurol 64:108-15. 2007
    ..Prognostic uncertainty suggests the need for additional measures to assist the clinician...
  55. ncbi ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions
    Lon S Schneider
    Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Alzheimer Dis Assoc Disord 20:S124-38. 2006
    ..An important consideration was whether global assessments are specific and sensitive measures of change during a prevention trial...
  56. ncbi Safety and acceptability of the research lumbar puncture
    Elaine R Peskind
    VA Puget Sound Health Care System, Mental Illness Research, Education and Clinical Center MIRECC, University of Washington School of Medicine, Seattle, WA 98108, USA
    Alzheimer Dis Assoc Disord 19:220-5. 2005
    ....
  57. ncbi FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease
    Norman L Foster
    Center for Alzheimer s Care, Imaging and Research and Department of Neurology, University of Utah, USA
    Brain 130:2616-35. 2007
    ..FDG-PET adds important information that appropriately increases diagnostic confidence, even among experienced dementia specialists...
  58. ncbi Frontotemporal lobar degeneration with motor neuron disease: a clinical and pathological spectrum
    Christopher M Clark
    Arch Neurol 63:489-90. 2006
  59. pmc Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials
    Mary Sano
    Mount Sinai School of Medicine, Bronx, NY, USA
    Alzheimer Dis Assoc Disord 20:232-41. 2006
    ....
  60. ncbi Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative
    Rosa Rademakers
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA
    Lancet Neurol 6:857-68. 2007
    ..The most common mutation in GRN is Arg493X. We aimed to establish the contribution of this mutation to FTLD and related disorders...
  61. ncbi A comparison of classification methods for differentiating fronto-temporal dementia from Alzheimer's disease using FDG-PET imaging
    Roger Higdon
    University of Washington, Seattle, USA
    Stat Med 23:315-26. 2004
    ..Methods using PLS appear to be more successful. Averaging or using VOI data may also be helpful...
  62. ncbi Informed consent for Alzheimer's disease clinical trials: a survey of clinical investigators
    Jason H T Karlawish
    Internal Ethics Committee of the Alzheimer s Disease Cooperative Study
    IRB 24:1-5. 2002
  63. pmc Comparative multiresolution wavelet analysis of ERP spectral bands using an ensemble of classifiers approach for early diagnosis of Alzheimer's disease
    Robi Polikar
    Electrical and Computer Engineering, Rowan University, Glassboro, NJ 08028, USA
    Comput Biol Med 37:542-58. 2007
    ..Surprising yet promising outcomes indicate that ERPs in response to novel sounds of oddball paradigm may be more reliable as a biomarker than the more commonly used responses to target sounds...
  64. ncbi Stacked generalization for early diagnosis of Alzheimer's disease
    Hardik Gandhi
    Dept of Electrical and Computer Engineering, Rowan University, Glassboro, NJ, USA
    Conf Proc IEEE Eng Med Biol Soc 1:5350-3. 2006
    ..Extracted features were then used to train an ensemble of classifiers based stacked generalization approach. We describe the approach, and present our promising preliminary results...
  65. pmc Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease
    Adam S Fleisher
    University of California, San Diego, La Jolla, CA 92037, USA
    Arch Neurol 65:1031-8. 2008
    ..To evaluate the safety, tolerability, and amyloid beta (Abeta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease...
  66. pmc Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years
    Gerda G Fillenbaum
    Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, NC, USA
    Alzheimers Dement 4:96-109. 2008
    ..CERAD materials and data remain available for those wishing to use them...
  67. pmc Implications for oxidative and nitrative stress in the pathogenesis of AIDS-related Kaposi's sarcoma
    Susan R Mallery
    Department of Oral Maxillofacial Surgery and Pathology, College of Dentistry, Ohio State University, Columbus, Ohio, USA
    Carcinogenesis 25:597-603. 2004
    ....